Reference health
Brain Volume Loss During the First Year of Interferon‐Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics
29/29 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
The 29 checked references that resolve
resolves10.1016/S1474-4422(06)70349-0
The measurement and clinical relevance of brain atrophy in multiple sclerosis
resolves10.1007/s00415-008-1009-1
The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome
resolves10.1016/S0140-6736(04)17271-1
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial
resolves10.1056/NEJMoa0909494
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
resolves10.1056/NEJMoa0907839
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
resolves10.1016/S0140-6736(12)61768-1
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
resolves10.1016/S0140-6736(12)61769-3
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
resolves10.1177/1352458512473190
Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes
resolves10.1177/135245850000600601
Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon β-1a
resolves10.1212/01.WNL.0000149516.30155.B8
Rate of brain atrophy in relapsing MS decreases during treatment with IFNβ-1a
resolves10.1177/1352458515599072
Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing−remitting multiple sclerosis: A retrospective analysis
resolves10.1212/NXI.0000000000000132
Predictive value of early brain atrophy on response in patients treated with interferon β
resolves10.1212/01.wnl.0000237994.95410.ce
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
resolves10.1046/j.1468-1331.2002.00476.x
A 6‐year clinical and MRI follow‐up study of patients with relapsing–remitting multiple sclerosis treated with Interferon‐beta
resolves10.1016/S1474-4422(12)70230-2
Measurement and clinical effect of grey matter pathology in multiple sclerosis
resolves10.1177/1352458514532317
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis
resolves10.1002/ana.21423
Gray matter atrophy is related to long‐term disability in multiple sclerosis
resolves10.1212/01.WNL.0000129544.79539.D5
Neocortical volume decrease in relapsing–remitting MS patients with mild cognitive impairment
resolves10.1212/01.wnl.0000316810.01120.05
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
resolves10.1191/1352458505ms1142oa
Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications
resolves10.1371/journal.pone.0091098
Effect of Treatment with Interferon Beta-1a on Changes in Voxel-Wise Magnetization Transfer Ratio in Normal Appearing Brain Tissue and Lesions of Patients with Relapsing–Remitting Multiple Sclerosis: A 24-Week, Controlled Pilot Study
resolves10.1177/1352458511433304
Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis
resolves10.1007/s00415-014-7504-7
Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study
resolves10.1093/brain/awh498
Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study
resolves10.1016/j.nicl.2013.10.015
Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis
resolves10.1016/j.neuroimage.2013.12.004
Improved longitudinal gray and white matter atrophy assessment via application of a 4-dimensional hidden Markov random field model
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1111/jon.12337"><img src="https://citestamp.com/citestamped/10.1111/jon.12337/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1111/jon.12337)